Arrowhead Pharmaceuticals Inc. (ARWR)

21.35
2.41 12.72
NASDAQ : Health Technology
Prev Close 18.94
Open 20.59
Day Low/High 20.49 / 22.74
52 Wk Low/High 9.56 / 22.39
Volume 11.60M
Avg Volume 1.40M
Exchange NASDAQ
Shares Outstanding 94.81M
Market Cap 1.85B
EPS -0.70
P/E Ratio 278.00
Div & Yield N.A. (N.A)
5 Health Care Stocks Under $10 to Watch

5 Health Care Stocks Under $10 to Watch

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Arrowhead Induces 90% Reduction In Hepatitis B Antigens In Chimpanzee With Chronic Infection: Data Follow Previous Report Of Reduction In Viral DNA

Arrowhead Induces 90% Reduction In Hepatitis B Antigens In Chimpanzee With Chronic Infection: Data Follow Previous Report Of Reduction In Viral DNA

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, will host an analyst event today in New York City to discuss ARC-520, its RNAi-based candidate designed to treat chronic hepatitis B virus...

Arrowhead RNAi Candidate ARC-520 Induces Greater Than 90% Reduction In Circulating HBV DNA In Chimpanzee With Chronic Hepatitis B

Arrowhead RNAi Candidate ARC-520 Induces Greater Than 90% Reduction In Circulating HBV DNA In Chimpanzee With Chronic Hepatitis B

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that a study of its RNAi-based candidate ARC-520 in a chimpanzee chronically infected with the human hepatitis B virus...

Arrowhead To Host Analyst Event In New York To Discuss RNAi-based Hepatitis B Candidate ARC-520

Arrowhead To Host Analyst Event In New York To Discuss RNAi-based Hepatitis B Candidate ARC-520

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it will host an analyst and investor event on Monday, March 25, from 12:30 to 2:00 p.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

Arrowhead Receives Notice Of Patent Allowance For New Protease Sensitive Masking Chemistry For DPC SiRNA Delivery System

Arrowhead Receives Notice Of Patent Allowance For New Protease Sensitive Masking Chemistry For DPC SiRNA Delivery System

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it has received a Notice of Allowance from the U.

Arrowhead Data Demonstrates RNAi Candidate ARC-520 Silences Hepatitis B Virus

Arrowhead Data Demonstrates RNAi Candidate ARC-520 Silences Hepatitis B Virus

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced the publication of data demonstrating multi-log reductions in hepatitis B viral DNA and proteins lasting over 30 days ...

4 Biotech Stocks Under $10 Moving Higher

4 Biotech Stocks Under $10 Moving Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Arrowhead Reports Fiscal 2013 First Quarter Financial Results

Arrowhead Reports Fiscal 2013 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced financial results for its fiscal 2013 first quarter ended December 31, 2012.

Arrowhead To Report Fiscal 2013 First Quarter Financial Results

Arrowhead To Report Fiscal 2013 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it will report its financial results for the fiscal 2013 first quarter ended December 31, 2012, on Wednesday, ...

Arrowhead To Present At Upcoming Scientific Conferences

Arrowhead To Present At Upcoming Scientific Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that academic collaborators and scientists from the company will present data on the Dynamic PolyConjugate™ (DPC) siRNA ...

Arrowhead Announces Pricing Of A Public Offering Of Common Stock And Warrants

Arrowhead Announces Pricing Of A Public Offering Of Common Stock And Warrants

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has priced a public offering of approximately 1.

Arrowhead Research Corporation Announces Proposed Public Offering Of Common Stock And Warrants

Arrowhead Research Corporation Announces Proposed Public Offering Of Common Stock And Warrants

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it intends to offer units consisting of shares of common stock and warrants in a public offering.

Arrowhead Reports Fiscal 2012 Fourth Quarter And Year-End Financial Results

Arrowhead Reports Fiscal 2012 Fourth Quarter And Year-End Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced financial results for its fiscal 2012 fourth quarter and year ended September 30, 2012.

Arrowhead And Shire Enter Into Collaboration And License Agreement To Develop Peptide-Targeted Therapeutics

Arrowhead And Shire Enter Into Collaboration And License Agreement To Develop Peptide-Targeted Therapeutics

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it has signed a research collaboration and license agreement with Shire AG, to develop and commercialize targeted ...

Arrowhead To Report Fiscal 2012 Fourth Quarter And Year-End Financial Results

Arrowhead To Report Fiscal 2012 Fourth Quarter And Year-End Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it will report its financial results for the fiscal 2012 fourth quarter and year ended September 30, 2012, on ...

Arrowhead Announces Pricing Of A Public Offering Of Common Stock And Warrants

Arrowhead Announces Pricing Of A Public Offering Of Common Stock And Warrants

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has priced a public offering of approximately 1.

Arrowhead Research Corporation Announces Proposed Public Offering Of Common Stock And Warrants

Arrowhead Research Corporation Announces Proposed Public Offering Of Common Stock And Warrants

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it intends to offer units consisting of shares of common stock and warrants in a public offering.

Arrowhead Publishes First Ever Cholesterol-siRNA Mediated Gene Knockdown In Primates And Novel DPC Co-Injection Strategy

Arrowhead Publishes First Ever Cholesterol-siRNA Mediated Gene Knockdown In Primates And Novel DPC Co-Injection Strategy

Arrowhead Research Corporation (NASDAQ:ARWR), a targeted therapeutics company, today announced the publication of data demonstrating that high level target gene knockdown with low doses of cholesterol-siRNA is possible...

Arrowhead Creates Hepatitis B Clinical Advisory Board And Names Dr. Robert Gish Chairman

Arrowhead Creates Hepatitis B Clinical Advisory Board And Names Dr. Robert Gish Chairman

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, announced today that prominent hepatologist Robert G.

Arrowhead Research To Present At BIO-Europe 2012

Arrowhead Research To Present At BIO-Europe 2012

Arrowhead Research Corporation (NASDAQ:ARWR), a targeted therapeutics company, today announced that Dr.

5 Stocks Under $10 Set to Trade Higher in November

5 Stocks Under $10 Set to Trade Higher in November

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

Arrowhead Presents Data Showing 99% Target Knockdown In Monkeys Without Toxicity Using Subcutaneous Formulation Of Dynamic Polyconjugate SiRNA Delivery System

Arrowhead Presents Data Showing 99% Target Knockdown In Monkeys Without Toxicity Using Subcutaneous Formulation Of Dynamic Polyconjugate SiRNA Delivery System

Arrowhead Research Corporation (NASDAQ:ARWR), a targeted therapeutics company, announced that David Lewis, Ph.

Arrowhead Research Receives Notice Of Patent Allowance For New Formulation Of DPC SiRNA Delivery System Showing 500-Fold Increase In Potency

Arrowhead Research Receives Notice Of Patent Allowance For New Formulation Of DPC SiRNA Delivery System Showing 500-Fold Increase In Potency

Arrowhead Research Corporation (NASDAQ:ARWR), a targeted therapeutics company, today announced that it received a Notice of Allowance from the U.

Arrowhead To Present At Rodman And Renshaw Annual Global Investment Conference

Arrowhead To Present At Rodman And Renshaw Annual Global Investment Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that its President and Chief Executive Officer, Dr.

Arrowhead Completes Enrollment In Phase 1b Trial Of RNAi Drug Candidate CALAA-01

Arrowhead Completes Enrollment In Phase 1b Trial Of RNAi Drug Candidate CALAA-01

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that, through its Calando Pharmaceuticals subsidiary, it has completed enrollment of a phase 1b clinical trial of ...

Arrowhead's Management Presents At 2012 Wedbush PacGrow Life Sciences Management Access Conference (Transcript)

Arrowhead's Management Presents At 2012 Wedbush PacGrow Life Sciences Management Access Conference (Transcript)

Arrowhead's Management Presents at 2012 Wedbush PacGrow Life Sciences Management Access Conference (Transcript)

Arrowhead Enters Into Antibody Candidate Evaluation Agreement With Merck

Arrowhead Enters Into Antibody Candidate Evaluation Agreement With Merck

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it entered into an agreement with Merck, through a subsidiary, to undertake an evaluation of a novel proprietary ...

Arrowhead Research Corporation's CEO Discusses F3Q12 Results - Earnings Call Transcript

Arrowhead Research Corporation's CEO Discusses F3Q12 Results - Earnings Call Transcript

Arrowhead Research Corporation's CEO Discusses F3Q12 Results - Earnings Call Transcript

Arrowhead Reports Fiscal 2012 Third Quarter Financial Results

Arrowhead Reports Fiscal 2012 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced financial results for its fiscal 2012 third quarter ended June 30, 2012.

TheStreet Quant Rating: D (Sell)